Publications (original articles or review articles) published in 2020 from OUS - Section for Preventive Cardiology
11 publications found
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
JAMA Cardiol, 5 (6), 709-713
DOI 10.1001/jamacardio.2020.0728, PubMed 32347887
Cardiovascular risk factors and body composition in adults with achondroplasia
Genet Med, 23 (4), 732-739
DOI 10.1038/s41436-020-01024-6, PubMed 33204020
Cognition After Lowering LDL-Cholesterol With Evolocumab
J Am Coll Cardiol, 75 (18), 2283-2293
DOI 10.1016/j.jacc.2020.03.039, PubMed 32381158
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
JAMA Cardiol, 5 (8), 952-957
DOI 10.1001/jamacardio.2020.0882, PubMed 32432684
Risk of cardiovascular disease after preventive salpingo-oophorectomy
Int J Gynecol Cancer, 30 (5), 575-582
DOI 10.1136/ijgc-2019-000856, PubMed 32332121
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
Atheroscler Suppl, 42, e49-e58
DOI 10.1016/j.atherosclerosissup.2021.01.009, PubMed 33589224
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Eur Heart J, 41 (1), 111-188
DOI 10.1093/eurheartj/ehz455, PubMed 31504418
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Circulation, 141 (20), 1600-1607
DOI 10.1161/CIRCULATIONAHA.120.046397, PubMed 32223429
Validation of the cardiovascular risk model NORRISK 2 in South Asians and people with diabetes
Scand Cardiovasc J, 55 (1), 56-62
DOI 10.1080/14017431.2020.1821909, PubMed 33073627
Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations
Curr Med Res Opin, 36 (5), 713-730
DOI 10.1080/03007995.2020.1729708, PubMed 32050807
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
JAMA Cardiol, 5 (7), 787-793
DOI 10.1001/jamacardio.2020.0764, PubMed 32347885